{"id":"W2568858752","doi":"10.1016/j.jaad.2016.11.043","title":"Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Secukinumab; Medicine; Dermatology Life Quality Index; Etanercept; Placebo; Quality of life (healthcare); Psoriasis Area and Severity Index; Randomized controlled trial; Psoriasis; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002801462,0.001425529,0.003284545,0.000365754,0.0004580118,0.001209388,0.0006711317,0.001684491,0.003939753],"category_scores_gemma":[0.002169463,0.0004655593,0.002978513,0.000388285,0.0009548595,0.001346117,0.0003262429,0.002995176,0.0005842881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005973331,"about_ca_system_score_gemma":0.0006857076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004997015,"about_ca_topic_score_gemma":0.001321723,"domain_scores_codex":[0.9990688,0.000423632,0.00009012827,0.0001487677,0.0000893563,0.000179369],"domain_scores_gemma":[0.9983991,0.0005561404,0.0005315932,0.0001478561,0.00009395114,0.0002715356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9182659,0.008924667,0.00158199,0.001251466,0.003273588,0.00009727118,0.00009449683,0.0005161495,0.008123139,0.0001335848,0.001147086,0.05659066],"study_design_scores_gemma":[0.7653809,0.2075087,0.01747844,0.0001709497,0.003544222,0.0002190922,0.00009082699,0.0005189219,0.002703605,0.0003112865,0.002021715,0.00005125284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9767703,0.01898224,0.0005790239,0.0007240473,0.0003942169,0.0005690779,0.0006245049,0.0001015105,0.001254982],"genre_scores_gemma":[0.9919752,0.004661285,0.0005235448,0.0005730781,0.0003059782,0.0004406067,0.0005360125,0.00002007336,0.0009642352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003939753,"threshold_uncertainty_score":0.01481575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09313924228473613,"score_gpt":0.3864747613679332,"score_spread":0.293335519083197,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}